Outcome of chronic granulomatous disease - Conventional treatment vs stem cell transplantation.

Cinzia DedieuMichael H AlbertNizar MahlaouiFabian HauckChristian HedrichUlrich BaumannKlaus WarnatzJoachim RoeslerCarsten SpeckmannJohannes SchulteAlain FischerStephane BlancheHorst Von BernuthJörn-Sven Kühl

Published in: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2020)

Chronic granulomatous disease patients undergoing HSCT until 8 years of age show excellent survival, but young children need more intense conditioning to avoid graft rejection. Risks and benefits of HSCT for adolescents and adults must still be weighed carefully.

Keyphrases

stem cell transplantation
patients undergoing
high dose
young adults
interstitial lung disease
physical activity
hematopoietic stem cell
risk assessment
climate change
free survival
idiopathic pulmonary fibrosis
smoking cessation